Caricamento...
SAT-635 Results of a Preclinical Pilot Study Evaluating 24-Hour Subcutaneous Infusion of the GLP-1 Analogue Liraglutide Delivered via the H-Patch Wearable Device
Nonalcoholic fatty liver disease (NAFLD) affects an estimated 30% of Americans, is the most common cause of chronic liver disease in the US, and a leading cause of liver-related morbidity/mortality worldwide(1). Currently, there are no FDA-approved drugs specifically tailored to NAFLD or its big bro...
Salvato in:
| Pubblicato in: | J Endocr Soc |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208354/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1739 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|